- CEO Morhet to Discuss Continued Expansion of DXL(TM) Patent Protection at
7th Annual BIO Investor Forum -
BRITISH COLUMBIA, Canada, Oct. 30 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced today that it has received patent grants in Germany, Spain, France, Great Britain and Italy further expanding patent protection of its DXL(TM) technology in Europe. The patents, titled "METHOD OF AFFINITY CROSS-LINKING BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES," relate to the Company's ability to create, develop and manufacture antibodies based on its DXL(TM) technology platform. The new patents name InNexus scientists as inventors and are solely owned by InNexus.
"These patent grants demonstrate our commitment to providing real value to our shareholders by protecting and ensuring exclusivity of our DXL(TM) technology. Our patent portfolio provides potential for future royalty and licensing deals or outright sales of our expanding and maturing family of DXL(TM) preclinical candidates," said Jeff Morhet, Chairman and CEO of InNexus. "Patents are the currency of our industry and these patent grants also provide InNexus with additional tools to prevent others from making, using and selling DXL(TM) antibodies."
CEO Morhet will present at the 7th Annual BIO Investor Forum on October 30, 2008 and his thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform, partnerships, company milestones and the recent European patent grants.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
|SOURCE InNexus Biotechnology Inc.|
Copyright©2008 PR Newswire.
All rights reserved